Truist Securities Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas maintains a 'Buy' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raises the price target from $125 to $140.
June 30, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's price target has been raised from $125 to $140 by Truist Securities, which maintains a 'Buy' rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase in the future. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100